BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - September 16, 2014) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) cardiovascular outcomes study.
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) will host a live
webcast of its fiscal 2015 first-quarter conference call on Wednesday,
October 29, 2014, at 3:45 p.m. CT (4:45 p.m. ET). David Martin,
President and Chief Executive Officer, and Larry Betterley, Chief
Financial Officer, will discuss the company’s results for its fiscal
first quarter ended September 30, 2014, and its financial outlook.
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today announced that
it has received CE (Conformité Européenne) Mark for its Stealth 360º
Orbital Atherectomy System (OAS). Stealth 360º is a percutaneous OAS
that is indicated to treat patients who suffer from peripheral arterial
“Securing CE Mark for Stealth 360º greatly expands our market
opportunity and is an important milestone toward benefiting patients in
Europe suffering from PAD—especially those with critical limb ischemia,
(CLI) who have been underserved by other treatment options,” said David
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device
company developing and commercializing innovative interventional
treatment systems for peripheral and coronary artery disease, today
reported financial results for its fiscal first quarter ended September
Squibb Company (NYSE: BMY) and Pfizer
Inc. (NYSE: PFE) today announced charitable donations totaling more
than $1 million to be granted between 2014 and 2016 to seven nonprofit
organizations that support patients with cardiovascular disease.
Sign-up for Sunshine Heart to Provide Clinical Updates From the North American Feasibility Study and OPTIONS HF European Post-Market Study at 2014 Transcatheter Cardiovascular Therapeutics (TCT) Conference investment picks
Sign-up for VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study investment picks
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.